Ijeoma Uchegbu

Last updated
Ijeoma Uchegbu
Ijeoma Uchegbu at the Oxford Union Science Debate 2018.png
Ijeoma Uchegbu at the Oxford Union Science Debate 2018
Alma mater University of Benin
University of Lagos
University of London
Known forNanoparticle drug delivery
Scientific career
Institutions University of Strathclyde
University College London
Website http://www.nanomerics.com

Ijeoma Uchegbu is a Nigerian-British Professor of Pharmacy at University College London where she held the position of Pro-Vice Provost for Africa and the Middle East. She is the Chief Scientific Officer of Nanomerics, a pharmaceutical nanotechnology company specialising in drug delivery solutions for poorly water-soluble drugs, nucleic acids and peptides. She is also a Governor of the Wellcome, a large biomedical research charity. Apart from her highly cited scientific research in Pharmaceutical Nanoscience, [1] Uchegbu is also known for her work in science public engagement and equality and diversity in Science, Technology, Engineering and Mathematics (STEM). [2] [3] In December 2023, it was announced that she will become President of Wolfson College, Cambridge in October 2024. [4]

Contents

Education and early career

Uchegbu grew up in Hackney and South East Nigeria. [5] She studied pharmacy at the University of Benin, graduating in 1981, and earned her master's degree at the University of Lagos. [6] She could not complete a PhD in Nigeria due to infrastructure difficulties in the 80s.

"I came into science simply because after training as a pharmacist I wanted something a little bit more challenging to do. I thought that being a researcher would be a great place to start. As I did my pharmacy degree at Nigeria’s University of Benin, I did give research a try in Nigeria, but the infrastructure difficulties in the eighties made this virtually impossible. I came back to the UK, having emigrated 17 years earlier from the UK to Nigeria and started looking around for opportunities." [7]

She moved back to the UK and completed her postgraduate studies at the University of London, graduating with a PhD in 1997. She was appointed a lecturer at the University of Strathclyde from 2002-2004.

Uchegbu has been elected President of Wolfson College, Cambridge and will take up the post commencing 1st October 2024. [8]

Research

Uchegbu was made a Chair in Drug Delivery at the University of Strathclyde in 2002. Here she worked on polymer self-assembly, identifying materials that could form stable nanosystems. [9] She demonstrated that polymer molecular weight could be used to control the size of vesicles. [10] She joined University College London in 2006 as a Chair in Pharmaceutical Nanoscience at the School of Pharmacy. [11] [12] Uchegbu leads a research group that investigate molecular design and dosage of pharmaceuticals. [13] She has designed polymers that self-assemble into nanoparticles with the appropriate properties to transport drugs. [13] She explores how nanoparticles can be used for drug delivery. [14] Uchegbu holds several patents for drug delivery, [15] [16] [17] [18] [19] [20] [21] [22] and biocompatible polymers. [23] [24] [25] Her pharmaceuticals deliver genes and siRNA to tumours and peptides to the brain as well as encouraging the absorption of hydrophobic drugs using nanoparticles. [26] She is exploring how nanomedicine can be used to treat brain tumours. [27] In 2018 she was part of a £5.7 million Engineering and Physical Sciences Research Council grant, Raman Nanotheranostics, that will use gold nanoparticles to identify disease and light to destroy diseased cells. [28] She also works with magnetic nanoparticles. [29] [30]

Nanomerics

In 2010 Uchegbu founded Nanomerics with Andreas Schätzlein. [31] Nanomerics is a pharmaceutical company that uses nanotechnology platforms to develop medicine. Uchegbu is the Chief Scientific Officer of Nanomerics. [9] Nanomerics are developing structures that can transport antibodies that can cross the blood–brain barrier. [32] Nanomerics develop molecular envelope technology nanoparticles from amphiphilic polymers that self-assemble. [33] She won the Royal Society of Chemistry Emerging Technologies prize for their molecular envelope technology in 2017. [34] She licensed the medicine NM133 to Iacta Pharmaceuticals in 2017. [33] NM133 contains cyclosporine A and can be used to treat dry eye. [33]

Professional service

Uchegbu serves on the editorial board of the Journal of Controlled Release. [35] She has served as the scientific secretary of the Controlled Release Society. She is editor-in-chief of Pharmaceutical Nanotechnology. [36] She is on the healthcare strategy advisory team of the Engineering and Physical Sciences Research Council. She was involved in the University College London celebrations of the National Health Service turning seventy. [37] In 2007 she was chosen for Women of Outstanding Achievement in SET Photographic Exhibition which was displayed at the Science Museum and the British Museum. [38]

In 2015 Uchegbu was appointed Pro-Vice Provost for Africa and the Middle East. [39] [40] She chairs the Africa and Middle East regional network at University College London, building partnerships and starting collaborative teams, welcoming international visitors and supporting student recruitment. [41]

Public Engagement and Equality and Diversity

Uchegbu is involved in public engagement and science communication and is featured in BBC Woman's Hour discussing her research into how nano particles can be used to help deliver drugs to the body [42] and taken part in Soapbox Science an international science outreach programme promoting women scientists and the work they do to members of the public. [7]

Uchegbu is also involved in equality and diversity activities and programmes, acting as the UCL Provost's Envoy for Race Equality [3] and featuring as the only Black British Role Model for the Women's Engineering Society. [2] She also serves on the University College London Race Equality Charter self-assessment team. [43] [44] She is part of the Black Female Professors Forum, representing 1 of the 55 female professors of colour and 1 of the 25 Black female professors in the UK in 2017. [45] [46]

Books

Awards and honours

Related Research Articles

Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials.

<span class="mw-page-title-main">Dendrimer</span> Highly ordered, branched polymeric molecule

Dendrimers are highly ordered, branched polymeric molecules. Synonymous terms for dendrimer include arborols and cascade molecules. Typically, dendrimers are symmetric about the core, and often adopt a spherical three-dimensional morphology. The word dendron is also encountered frequently. A dendron usually contains a single chemically addressable group called the focal point or core. The difference between dendrons and dendrimers is illustrated in the top figure, but the terms are typically encountered interchangeably.

Targeted drug delivery, sometimes called smart drug delivery, is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more uniform effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult, and the reduced ability to adjust the dosages.

Modified-release dosage is a mechanism that delivers a drug with a delay after its administration or for a prolonged period of time or to a specific target in the body.

<span class="mw-page-title-main">Solid lipid nanoparticle</span> Novel drug delivery system

Lipid nanoparticles (LNPs) are nanoparticles composed of lipids. They are a novel pharmaceutical drug delivery system, and a novel pharmaceutical formulation. LNPs as a drug delivery vehicle were first approved in 2018 for the siRNA drug Onpattro. LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle.

The UCL Faculty of Life Sciences is one of the 11 constituent faculties of University College London (UCL).

<span class="mw-page-title-main">Jindřich Kopeček</span> American chemist (born 1940)

Jindřich Henry Kopeček was born in Strakonice, Czech Republic, as the son of Jan and Herta Zita (Krombholz) Kopeček. He is distinguished professor of pharmaceutical chemistry and distinguished professor of biomedical engineering at the University of Utah in Salt Lake City, Utah. Kopeček is also an honorary professor at Sichuan University in Chengdu, China. His research focuses on biorecognition of macromolecules, bioconjugate chemistry, drug delivery systems, self-assembled biomaterials, and drug-free macromolecular therapeutics.

Nanoparticles for drug delivery to the brain is a method for transporting drug molecules across the blood–brain barrier (BBB) using nanoparticles. These drugs cross the BBB and deliver pharmaceuticals to the brain for therapeutic treatment of neurological disorders. These disorders include Parkinson's disease, Alzheimer's disease, schizophrenia, depression, and brain tumors. Part of the difficulty in finding cures for these central nervous system (CNS) disorders is that there is yet no truly efficient delivery method for drugs to cross the BBB. Antibiotics, antineoplastic agents, and a variety of CNS-active drugs, especially neuropeptides, are a few examples of molecules that cannot pass the BBB alone. With the aid of nanoparticle delivery systems, however, studies have shown that some drugs can now cross the BBB, and even exhibit lower toxicity and decrease adverse effects throughout the body. Toxicity is an important concept for pharmacology because high toxicity levels in the body could be detrimental to the patient by affecting other organs and disrupting their function. Further, the BBB is not the only physiological barrier for drug delivery to the brain. Other biological factors influence how drugs are transported throughout the body and how they target specific locations for action. Some of these pathophysiological factors include blood flow alterations, edema and increased intracranial pressure, metabolic perturbations, and altered gene expression and protein synthesis. Though there exist many obstacles that make developing a robust delivery system difficult, nanoparticles provide a promising mechanism for drug transport to the CNS.

Vladimir Petrovich Torchilin is a Soviet, Russian and American biochemist, pharmacologist, and an expert in medical nanotechnology. Torchillin is a University Distinguished Professor of Pharmaceutical Sciences at Northeastern University. He also serves as a director at both the Center for Translational Cancer Nanomedicine and at the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University.

<span class="mw-page-title-main">Eugenia Kumacheva</span> Canadian chemist

Eugenia Kumacheva is a University Professor and Distinguished Professor of Chemistry at the University of Toronto. Her research interests span across the fields of fundamental and applied polymers science, nanotechnology, microfluidics, and interface chemistry. She was awarded the L'Oréal-UNESCO Awards for Women in Science in 2008 "for the design and development of new materials with many applications including targeted drug delivery for cancer treatments and materials for high density optical data storage". In 2011, she published a book on the Microfluidic Reactors for Polymer Particles co-authored with Piotr Garstecki. She is Canadian Research Chair in Advanced Polymer Materials. She is Fellow of the Royal Society (FRS) and a Fellow of the Royal Society of Canada (FRSC).

<span class="mw-page-title-main">Andreas Bernkop-Schnürch</span> Austrian university teacher (born 1965)

Andreas Bernkop-Schnürch is an Austrian scientist and entrepreneur, who is Head of the Department of Pharmaceutical Technology in the Institute of Pharmacy at the University of Innsbruck.

Mojisola Christianah Adeyeye is a Nigerian pharmacist and professor. She was appointed the Director-General of National Agency for Food and Drug Administration and Control (NAFDAC) on 3 November 2017 by the President of The Federal Republic of Nigeria, Muhammadu Buhari. Before her appointment as NAFDAC boss, she was the founding Chair of Biopharmaceutical Sciences and a Professor of Pharmaceutics, Manufacturing Science and Drug Product Evaluation at the College of Pharmacy, Roosevelt University in Schaumburg, Illinois, where she spent 7 years. She was also a Professor of Pharmaceutics and Manufacturing for 21 years at Duquesne University in Pittsburgh, Pennsylvania, USA. She is Senior Fulbright Scholar and Specialist and 2008 American Association of Pharmaceutical Scientists Fellow. She is also a Fellow of the Nigerian Academy of Science and Nigeria Academy of Pharmacy. Her research interests are in the areas of pre-formulation, early phase development of solid, semisolid and liquid dosage forms, and IND-based and intellectual property-driven late phase drug product development. She is the founder and President of Elim Pediatric Pharmaceuticals Rolling Meadows, Illinois. Through Duquesne University, she was able to develop an anti-retroviral (HIV/AIDS) pediatric fixed-dose combination and received intellectual property on the formulations in the UK and South Africa.

Christine Allen is a Canadian professor and the first associate vice-president and vice-provost for strategic initiatives at the University of Toronto. She served formerly as interim dean of the university's Leslie Dan Faculty of Pharmacy. She is co-founder of Nanovista, a company focused on imaging of tumors. She also works as the associate editor of Molecular Pharmaceutics.

Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.

<span class="mw-page-title-main">Nguyen TK Thanh</span> Vietnamese nanotechnologist

Nguyễn Thị Kim Thanh is a professor of Nanomaterials at University College London. She was awarded the 2019 Royal Society Rosalind Franklin Award for her research and efforts toward gender equality.

Hamid Ghandehari is an Iranian-American drug delivery research scientist, and a professor in the Departments of Pharmaceutics and Pharmaceutical Chemistry and Biomedical Engineering at the University of Utah. His research is focused in recombinant polymers for drug and gene delivery, nanotoxicology of dendritic and inorganic constructs, water-soluble polymers for targeted delivery and poly(amidoamine) dendrimers for oral delivery.

<span class="mw-page-title-main">Reduction-sensitive nanoparticles</span> Drug delivery method

Reduction-sensitive nanoparticles (RSNP) consist of nanocarriers that are chemically responsive to reduction. Drug delivery systems using RSNP can be loaded with different drugs that are designed to be released within a concentrated reducing environment, such as the tumor-targeted microenvironment. Reduction-Sensitive Nanoparticles provide an efficient method of targeted drug delivery for the improved controlled release of medication within localized areas of the body.

Vitaliy Khutoryanskiy FRSC is a British and Kazakhstani scientist, a Professor of Formulation Science and a Royal Society Industry Fellow at the University of Reading. His research focuses on polymers, biomaterials, nanomaterials, drug delivery, and pharmaceutical sciences. Khutoryanskiy has published over 200 original research articles, book chapters, and reviews. His publications have attracted > 11000 citations and his current h-index is 51. He received several prestigious awards in recognition for his research in polymers, colloids and drug delivery as well as for contributions to research peer-review and mentoring of early career researchers. He holds several honorary professorship titles from different universities.

<span class="mw-page-title-main">Alexander Kabanov (chemist)</span>

Alexander Viktorovich Kabanov, is a Russian and American chemist, an educator, an entrepreneur, and a researcher in the fields of drug delivery and nanomedicine.

Moein Moghimi is a British professor and researcher in the fields of nanomedicine, drug delivery and biomaterials. He is currently the professor of Pharmaceutics and Nanomedicine at the School of Pharmacy and the Translational and Clinical Research Institute at Newcastle University. He is also an adjoint professor at the Skaggs School of Pharmacy, University of Colorado Denver.

References

  1. ↑ "Ijeoma Uchegbu - Google Scholar Citations". scholar.google.co.uk. Retrieved 2019-02-28.
  2. 1 2 "Role models | Women's Engineering Society". wes.org.uk. Archived from the original on 2019-03-01. Retrieved 2019-02-28.
  3. 1 2 UCL (2018-07-12). "Deans pledge to further race equality at UCL". UCL Human Resources. Retrieved 2019-02-28.
  4. ↑ Wolfson College, Cambridge (2023-12-09). "Wolfson College Announces its Next President".
  5. ↑ "International Women's Day 2015: What inspired some of UCL's leading women to become academics?". ucl.ac.uk. 2015-03-05. Retrieved 2018-10-21.
  6. ↑ Editors, BioPharm International (2 December 2006). "The Talent Pool". Biopharm International. BioPharm International-12-02-2006. 2006 (7). Retrieved 2018-10-21.{{cite journal}}: |last= has generic name (help)
  7. 1 2 "Barriers are there to be broken: Meet Ijeoma F. Uchegbu - SoapboxScience". SoapboxScience. 2017-05-24. Retrieved 2018-10-21.
  8. ↑ reports, Agency (2023-12-17). "Tinubu congratulates Nigerian, Ijeoma Uchegbu, elected Cambridge varsity college president". Tribune Online. Retrieved 2023-12-19.
  9. 1 2 "Ijeoma Uchegbu | Nanomerics". nanomerics.com. Retrieved 2018-10-21.
  10. ↑ Wang, Wei; McConaghy, Anne Marie; Tetley, Laurence; Uchegbu, Ijeoma F. (February 2001). "Controls on Polymer Molecular Weight May Be Used To Control the Size of Palmitoyl Glycol Chitosan Polymeric Vesicles". Langmuir. 17 (3): 631–636. doi:10.1021/la001078w. ISSN   0743-7463.
  11. ↑ UCLGlobalHealth (2013-09-12), The Latest Developments in Pharmaceutical Nanoscience - Ijeoma Uchegbu , retrieved 2018-10-21
  12. ↑ UCL SLMS (2018-05-15), Meet the Researchers and Educators | Ijeoma Uchegbu , retrieved 2018-10-21
  13. 1 2 3 UCL (2018-04-25). "Professor Ijeoma Uchegbu". UCL School of Pharmacy. Retrieved 2018-10-21.
  14. ↑ Godfrey, Lisa; Iannitelli, Antonio; Garrett, Natalie L.; Moger, Julian; Imbert, Ian; King, Tamara; Porreca, Frank; Soundararajan, Ramesh; Lalatsa, Aikaterini; Schätzlein, Andreas G.; Uchegbu, Ijeoma F. (2018-01-28). "Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia". Journal of Controlled Release. 270: 135–144. doi: 10.1016/j.jconrel.2017.11.041 . hdl: 10871/34693 . ISSN   0168-3659. PMID   29191784.
  15. ↑ "US Patent Application for Delivery of Drugs Patent Application (Application #20160279189 issued September 29, 2016) - Justia Patents Search". patents.justia.com. Retrieved 2018-10-21.
  16. ↑ "US Patent for Delivery of hydrophilic drugs Patent (Patent # 8,920,819 issued December 30, 2014) - Justia Patents Search". patents.justia.com. Retrieved 2018-10-21.
  17. ↑ "US Patent Application for Delivery of Hydrophilic Peptides Patent Application (Application #20130203647 issued August 8, 2013) - Justia Patents Search". patents.justia.com. Retrieved 2018-10-21.
  18. ↑ "US Patent Application for Delivery of Hydrophilic Drugs Patent Application (Application #20130034590 issued February 7, 2013) - Justia Patents Search". patents.justia.com. Retrieved 2018-10-21.
  19. ↑ "US Patent for Delivery of hydrophilic drugs Patent (Patent # 8,278,277 issued October 2, 2012) - Justia Patents Search". patents.justia.com. Retrieved 2018-10-21.
  20. ↑ "US Patent Application for DELIVERY OF HYDROPHILIC DRUGS Patent Application (Application #20100222281 issued September 2, 2010) - Justia Patents Search". patents.justia.com. Retrieved 2018-10-21.
  21. ↑ "US Patent Application for Drug delivery Patent Application (Application #20060148982 issued July 6, 2006) - Justia Patents Search". patents.justia.com. Retrieved 2018-10-21.
  22. ↑ "US Patent Application for Dendrimers for use in targeted delivery Patent Application (Application #20050019923 issued January 27, 2005) - Justia Patents Search". patents.justia.com. Retrieved 2018-10-21.
  23. ↑ "US Patent for Solubilising polysaccharides substituted with dydrophilic and hydrophobic groups Patent (Patent # 7,741,474 issued June 22, 2010) - Justia Patents Search". patents.justia.com. Retrieved 2018-10-21.
  24. ↑ "US Patent Application for Bioactive Polymers Patent Application (Application #20080267903 issued October 30, 2008) - Justia Patents Search". patents.justia.com. Retrieved 2018-10-21.
  25. ↑ "US Patent Application for Solubilising polysaccharides substituted with dydrophilic and hydrophobic groups Patent Application (Application #20060167116 issued July 27, 2006) - Justia Patents Search". patents.justia.com. Retrieved 2018-10-21.
  26. ↑ "Iris View Profile". iris.ucl.ac.uk. Retrieved 2018-10-21.
  27. ↑ Fisusi, Funmilola A; Schätzlein, Andreas G; Uchegbu, Ijeoma F (March 2018). "Nanomedicines in the treatment of brain tumors". Nanomedicine. 13 (6): 579–583. doi: 10.2217/nnm-2017-0378 . ISSN   1743-5889. PMID   29376468.
  28. ↑ "EPSRC grant to revolutionise detection and treatment of life-threatening illnesses". restless.org.uk. 2018-02-16. Archived from the original on 2018-10-21. Retrieved 2018-10-21.
  29. ↑ Hobson, Nicholas J.; Weng, Xian; Ashford, Marianne; Thanh, Nguyen T. K.; Schätzlein, Andreas G.; Uchegbu, Ijeoma F. (2019-06-05). "Facile aqueous, room temperature preparation of high transverse relaxivity clustered iron oxide nanoparticles". Colloids and Surfaces A: Physicochemical and Engineering Aspects. 570: 165–171. doi:10.1016/j.colsurfa.2019.03.023. ISSN   0927-7757. S2CID   96426043.
  30. ↑ Hobson, Nicholas J; Weng, Xian; Siow, Bernard; Veiga, Catarina; Ashford, Marianne; Thanh, Nguyen TK; Schätzlein, Andreas G; Uchegbu, Ijeoma F (2019-05-01). "Clustering superparamagnetic iron oxide nanoparticles produces organ-targeted high-contrast magnetic resonance images". Nanomedicine. 14 (9): 1135–1152. doi: 10.2217/nnm-2018-0370 . ISSN   1743-5889. PMID   31050589.
  31. ↑ "Studying small things can lead to big opportunities says UCL Chair in Pharmaceutical Nanoscience | etrust". etrust.org.uk. Retrieved 2018-10-21.
  32. ↑ "UCL spin-out aims to smuggle antibodies across the blood-brain barrier". biopharma-reporter.com. Retrieved 2018-10-21.
  33. 1 2 3 "IACTA Pharmaceuticals Licenses NM133 from Nanomerics for Treatment of Dry Eye" . Retrieved 2018-10-21.
  34. ↑ Iwasiewicz-Wabnig, Agnieszka (2017-10-05). "Innovation Seminar Series - Prof. Ijeoma Uchegbu, Nanomerics". maxwell.cam.ac.uk. Retrieved 2018-10-21.
  35. ↑ Elsevier. "I. Uchegbu - Editorial board - Journal of Controlled Release - ISSN 0168-3659". elsevier.com. Retrieved 2018-10-21.
  36. ↑ "Acknowledgements to Reviewers". eurekaselect.com. Retrieved 2018-10-21.
  37. ↑ "Professor Ijeoma Uchegbu". ucl.ac.uk. Retrieved 2018-10-21.
  38. ↑ Pearson, James (12 March 2007). "Women of Outstanding Achievement". electricalreview.co.uk. Retrieved 2018-10-21.
  39. ↑ UCL (2015-10-30). "Ijeoma Uchegbu Appointed UCL's Pro-Vice Provost for Africa and The Middle East". UCL School of Pharmacy. Retrieved 2018-10-21.
  40. ↑ UCL (2017-06-29). "Pro-Vice-Provosts (Regional)". UCL Global. Retrieved 2018-10-21.
  41. ↑ "Spotlight on Professor Ijeoma F. Uchegbu, Pro-Vice-Provost for Africa and the Middle East". ucl.ac.uk. 2016-01-14. Retrieved 2018-10-21.
  42. ↑ "27/09/2010, Woman's Hour - BBC Radio 4". BBC. Retrieved 2019-02-28.
  43. ↑ UCL (2018-07-11). "Deans pledge to further race equality at UCL". UCL Human Resources. Retrieved 2018-10-21.
  44. ↑ Letters (2016-11-01). "University College London is determined to tackle racism | Letters". the Guardian. Retrieved 2018-10-21.
  45. ↑ Solanke, Iyiola (2019-02-28). "Black Female Professors in the UK (February 2017)" (PDF). Equality Policy Unit. University of Leeds. Archived from the original (PDF) on 2019-03-01. Retrieved 2019-02-28.
  46. ↑ "Ijeoma Uchegbu – Black Female Professors Forum". blackfemaleprofessorsforum.org. Retrieved 2018-10-21.
  47. ↑ Uchegbu, L. F. (2000-02-01). Synthetic Surfactant Vesicles: Niosomes and Other Non-Phospholipid Vesicular Systems (1st ed.). Amsterdam: CRC Press. ISBN   9789058230119.
  48. ↑ Uchegbu, Ijeoma F.; Schatzlein, Andreas G., eds. (2006-05-19). Polymers in Drug Delivery (1st ed.). Boca Raton, Fla.: CRC Press. ISBN   9780849325335.
  49. ↑ Uchegbu, Ijeoma F.; Schatzlein, Andreas; Cheng, Woei Ping, eds. (2013-12-09). Fundamentals of Pharmaceutical Nanoscience (2013 ed.). New York; Heidelberg: Springer. ISBN   9781461491637.
  50. ↑ "2012 RPS award winners announced". Pharmaceutical Journal. Retrieved 2018-10-21.
  51. ↑ "Academy of Pharmaceutical Sciences Eminent Fellows". APSGB. Archived from the original on 2018-10-21. Retrieved 2018-10-21.
  52. ↑ "College of Fellows Award Recipients". controlledreleasesociety.org. Retrieved 2018-10-21.
  53. ↑ UCL (2016-11-09). "Professor Ijeoma Uchegbu wins Innovative Science Award". UCL School of Pharmacy. Retrieved 2018-10-21.
  54. ↑ "Honorary Fellows at the Royal Society of Chemistry".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.